NCT05950139View on ClinicalTrials.gov

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2029

Conditions
NSCLC Stage IVALK Fusion Protein Expression
Interventions
BIOLOGICAL

Peptide vaccine

Peptide vaccine

Trial Locations (1)

21287

RECRUITING

Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

Oncovir, Inc.
All Listed Sponsors
collaborator

Oncovir, Inc.

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER